BackGeneDx Holdings Overview
GeneDx Holdings Corp - Class A

GeneDx Holdings Return on Equity

Latest ROE for GeneDx Holdings: -45.38% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

-45.38%

Return on Equity

-45.38%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

GeneDx Holdings (SMFR) FAQ

The latest ROE for SMFR is -45.38%. That is below the Healthcare sector average of 13.1%. Investors often review this figure alongside GeneDx Holdings's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, SMFR currently prints -45.38% for ROE, while the sector average sits near 13.1%. That is roughly 446.3% below the sector mean. Large gaps often invite a closer look at GeneDx Holdings's growth, margins, and balance sheet.

Return on Equity shows how effectively GeneDx Holdings converts resources into returns. At -45.38%, SMFR may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SMFR's ROE (-45.38%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack GeneDx Holdings's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.